The Cost of Treatment with Dupilumab in Severe Asthma Patients With Coexisting Other Type 2 Inflammatory Diseases

Speaker(s)

Polkowska M1, Macioch T2, Lis J3
1Sanofi, Warsaw, MZ, Poland, 2Medical University of Warsaw, Warsaw, Poland, 3Sanofi, Warsaw, Poland

OBJECTIVES: Type 2 inflammation plays an important role in pathogenesis of asthma, atopic dermatitis, allergic rhinosinusitis and eosinophilic esophagitis. When these diseases coexist, they can further add to the patient’s overall disease burden and treatment cost. While other immunotherapies usually cover asthma treatment and chronic rhinosinusitis with nasal polyps (CRSwNP), dupilumab indication covers also atopic dermatitis and eosinophilic esophagitis. The aim of this analysis is to compare the cost of dupilumab treatment with the cost of other therapeutic options commonly used in Poland in severe asthma patients with the coexistence of other type 2 inflammatory diseases.

METHODS: Published data on the prevalence of the coexistence of type 2 inflammatory diseases and Polish data on asthma epidemiology were used to estimate the number of asthma patients with coexisting other type 2 inflammatory diseases in Poland. Current official MoH and NHF data on treatment cost and DRG pricing were used to calculate annual treatment costs of each disease. Data are presented in EUR (1 EUR=4,5 PLN).

RESULTS:

Published data show that up to 45% and 25% of asthma patients are diagnosed with CRSwNP and atopic dermatitis, respectively, with up to 4% being diagnosed with both of them. Because of high prevalence of coexisting type 2 inflammatory diseases and high cost of its additional treatment, asthma patients treated with dupilumab have in fact significantly lower total cost of treatment by 51.6%, 49.4% and 51.5% compared to patients treated with omalizumab, mepolizumab and benralizumab, respectively. Given the current number of asthma patients treated with immunotherapy in Poland (1843), treatment with dupilumab may result in savings to NHF budget by EUR 5,77 million.

CONCLUSIONS: The cost of coexisting type 2 inflammatory diseases should be considered when comparing cost of immunotherapies used for severe asthma treatment.

Code

EE489

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)